Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and BTB domain-containing protein 24 (ZBTB24) is a member of the BTB-zinc finger family of transcription factors characterized by the presence of an N-terminal BTB (POZ) domain, a C-terminal domain with eight tandem C2H2-type zinc fingers, and an AT-hook motif[1][4][5]. The protein is highly conserved and plays a critical role in transcriptional activation, shown to positively regulate genes including CDCA7[1][4]. ZBTB24 mutations cause immunodeficiency, centromeric instability, and facial anomalies syndrome type 2 (ICF2), a rare autosomal recessive disorder marked by DNA hypomethylation and antibody deficiency[1][4][5]. Disease-associated missense mutations in ZBTB24 disrupt its DNA-binding or chromatin localization functions, impairing downstream gene activation[1][4]. While ZBTB24 is central in genomic stability and immune system function, there are currently no drug interactions or therapeutic targeting strategies reported[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and BTB domain-containing protein 24 (ZBTB24).